1. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S, Albuquerque RJ, Hauswirth WW, Chiodo VA, Kugel JF, Goodrich JA, Ponicsan SL, Chaudhuri G, Murphy MP, Dunaief JL, Ambati BK, Ogura Y, Yoo JW, Lee DK, Provost P, Hinton DR, Nunez G, Baffi JZ, Kleinman ME, Ambati J. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012;149:847-859.
2. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001;73:887-896.
3. Nordgaard CL, Karunadharma PP, Feng X, Olsen TW, Ferrington DA. Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:2848-2855.
5. van Asten F, Simmons M, Singhal A, Keenan TD, Ratnapriya R, Agron E, Clemons TE, Swaroop A, Lu Z, Chew EY; Age-Related Eye Disease Study 2 Research Group. A deep phenotype association study reveals specific phenotype associations with genetic variants in age-related macular degeneration: age-related eye disease study 2 (AREDS2) report no. 14. Ophthalmology 2018;125:559-568.
6. Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119:2304-2311.
11. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF, Rougier MB, Malet F, Le Goff M, Dartigues JF, Colin J, Barberger-Gateau P, Delcourt C. Long-term blood pressure and age-related macular degeneration: the ALIENOR study. Invest Ophthalmol Vis Sci 2013;54:1905-1912.
14. Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R; Preferential Hyperacuity Perimeter Research Group. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005;25:296-303.
16. Rhoades W, Dickson D, Do DV. Potential role of lampalizumab for treatment of geographic atrophy. Clin Ophthalmol 2015;9:1049-1056.
17. Tsai JC. Canadian Journal of Ophthalmology Lecture: translational research advances in glaucoma neuroprotection. Can J Ophthalmol 2013;48:141-145.
19. Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509-516.
20. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Soren-son J, Freund KB. Visual and anatomical outcomes of intra-vitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33:1605-1612.
21. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013;156:15-22.
22. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97:1032-1035.
24. Blanco-Garavito R, Jung C, Uzzan J, Quaranta-ElMaftouhi M, Coscas F, Sahel J, Korobelnik JF, Bechet S, Querques G, Souied EH. Aflibercept after ranibizumab intravitreal injections in exudative age-related macular degeneration: the ARI2 study. Retina 2017;12. 21. [Epub]. 10.1097/IAE.0000000000001928.
25. Kim JH, Cho NC, Kim WJ. Intravitreal aflibercept for neovascular age-related macular degeneration resistant to bevacizumab and ranibizumab. J Korean Ophthalmol Soc 2015;56:1359-1364.
26. Kim KM, Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Efficacy of three aflibercept injections for neovascular age-related macular degeneration showing limited response to ranibizumab. J Korean Ophthalmol Soc 2017;58:62-68.
28. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 2017;390:50-61.
29. Soderberg AC, Algvere PV, Hengstler JC, Soderberg P, Seregard S, Kvanta A. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. Br J Ophthalmol 2012;96:714-718.
30. Ranjbar M, Kurz M, Holzhey A, Melchert C, Rades D, Grisanti S. Stereotactic radiotherapy in neovascular age-related macular degeneration: real-life efficacy and morphological evaluation of the outer retina-choroid complex. Medicine (Baltimore) 2016;95:e5729.
31. da Cruz L, Fynes K, Georgiadis O, Kerby J, Luo YH, Ahmado A, Vernon A, Daniels JT, Nommiste B, Hasan SM, Gooljar SB, Carr AF, Vugler A, Ramsden CM, Bictash M, Fenster M, Steer J, Harbinson T, Wilbrey A, Tufail A, Feng G, Whitlock M, Robson AG, Holder GE, Sagoo MS, Loudon PT, Whiting P, Coffey PJ. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol 2018;36:328-337.